Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus sigvotatug vedotin in advanced non-small cell lung cancer
2025-523526-40-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of PF-08634404 and sigvotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Adverse events, Dose-limiting toxicities and 1 more. Planned start Aug 2026; status: authorised.
02
Drugs
PF-08634404sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523526-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523526-40-00.